Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array)
HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase
- Product No.CMA717Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length4h
- Detection Range0.0098-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.0033ng/mL.
- DownloadInstruction Manual
- UOM 48T96T
- FOB
US$ 529
US$ 756
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 91-105 | 101 |
| EDTA plasma(n=5) | 90-97 | 93 |
| heparin plasma(n=5) | 90-99 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-90% | 86-93% | 96-104% | 86-101% |
| EDTA plasma(n=5) | 98-105% | 84-102% | 89-105% | 78-101% |
| heparin plasma(n=5) | 80-93% | 99-105% | 99-105% | 79-94% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| J Crohns Colitis. | Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. Pubmed:25518051 |
| J Crohns | Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin C PubMed: 25518051 |
| Molecular Biology Reports | Increased ENT2 Expression and Its Association With Altered Purine Metabolism in Different Stages of Colorectal Cancer Cell Lines |